Ron H N van Schaik

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. pmc Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients
    Hilde R H de Geus
    Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Nephrol 14:273. 2013
  2. pmc Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
    Nynke G L Jager
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    BMC Cancer 13:612. 2013
  3. pmc CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
    K Beelen
    Department of Molecular Biology and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Breast Cancer Res Treat 139:649-55. 2013
  4. ncbi request reprint Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents
    Ron H N van Schaik
    Department of Clinical Chemistry, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Ther Drug Monit 26:236-40. 2004
  5. ncbi request reprint Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
    Ron H N van Schaik
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Invest New Drugs 23:513-22. 2005
  6. doi request reprint The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
    Ron H N van Schaik
    Erasmus MC Rotterdam, The Netherlands
    Pharmacogenomics 12:1137-46. 2011
  7. doi request reprint CYP450 pharmacogenetics for personalizing cancer therapy
    Ron H N van Schaik
    Department of Clinical Chemistry, Erasmus University Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Drug Resist Updat 11:77-98. 2008
  8. doi request reprint UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients
    R H N Van Schaik
    Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Clin Pharmacol Ther 86:319-27. 2009
  9. ncbi request reprint Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants
    Loes E Visser
    Pharmacoepidemiology Unit, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Clin Pharmacol Ther 77:479-85. 2005
  10. doi request reprint The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
    Monique J Bijl
    Department of Epidemiology, Erasmus MC, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 118:125-30. 2009

Detail Information

Publications89

  1. pmc Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients
    Hilde R H de Geus
    Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Nephrol 14:273. 2013
    ..We studied the influence of timing on the predictive values of tubular proteins, measured before the rise of serum creatinine (SCr) in critically ill, non-septic patients...
  2. pmc Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
    Nynke G L Jager
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    BMC Cancer 13:612. 2013
    ..Serum concentrations of the active metabolite, endoxifen, may be positively related to treatment outcome. In addition, hot flashes are suggested to be positively associated with tamoxifen treatment outcome...
  3. pmc CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
    K Beelen
    Department of Molecular Biology and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Breast Cancer Res Treat 139:649-55. 2013
    ..In conclusion, breast cancer patients carrying at least one CYP2C19 2 allele have an adverse prognosis in the absence of adjuvant systemic treatment, which can be substantially improved by adjuvant tamoxifen treatment...
  4. ncbi request reprint Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents
    Ron H N van Schaik
    Department of Clinical Chemistry, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Ther Drug Monit 26:236-40. 2004
    ....
  5. ncbi request reprint Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
    Ron H N van Schaik
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Invest New Drugs 23:513-22. 2005
    ..For this latter enzyme, the drugs of interest still need to be identified...
  6. doi request reprint The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
    Ron H N van Schaik
    Erasmus MC Rotterdam, The Netherlands
    Pharmacogenomics 12:1137-46. 2011
    ..Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen. Here, we aimed to confirm this in a large group of 499 patients...
  7. doi request reprint CYP450 pharmacogenetics for personalizing cancer therapy
    Ron H N van Schaik
    Department of Clinical Chemistry, Erasmus University Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Drug Resist Updat 11:77-98. 2008
    ....
  8. doi request reprint UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients
    R H N Van Schaik
    Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Clin Pharmacol Ther 86:319-27. 2009
    ..3, 95% confidence interval 1.1-162.3; P < 0.05). UGT1A9 -275T>A and/or -2152C>T genotyping may identify patients at risk of MPA underexposure and acute rejection when receiving treatment with MMF and tacrolimus...
  9. ncbi request reprint Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants
    Loes E Visser
    Pharmacoepidemiology Unit, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Clin Pharmacol Ther 77:479-85. 2005
    ..We investigated whether NSAIDs were associated with overanticoagulation during therapy with coumarins and evaluated the effect of the CYP2C9 polymorphisms on this potential interaction...
  10. doi request reprint The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
    Monique J Bijl
    Department of Epidemiology, Erasmus MC, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 118:125-30. 2009
    ..The risk of breast cancer mortality is increased in tamoxifen users with decreased CYP2D6 activity, consistent with the model in which endoxifen formation is dependent on CYP2D6 activity...
  11. ncbi request reprint The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9
    Loes E Visser
    Department of Epidemiology, Erasmus MC, Rotterdam, Inspectorate for Health Care, The Hague, The Netherlands
    Pharmacogenet Genomics 17:473-9. 2007
    ..The aim of the present follow-up study was to investigate whether the enzyme activity of the human cytochrome P450 (CYP) 2C9 isoenzyme is associated with myocardial infarction...
  12. ncbi request reprint The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
    Loes E Visser
    Department of Internal Medicine, Erasmus MC, 3000 DR Rotterdam, The Netherlands
    Thromb Haemost 92:61-6. 2004
    ....
  13. doi request reprint Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients
    Rachida Bouamar
    PharmD, Department of Hospital Pharmacy, Erasmus Medical Center, P O Box 2040, CA Rotterdam 3000, The Netherlands
    Pharmacogenet Genomics 22:399-407. 2012
    ..We investigated the association between genetic polymorphisms in ABCB1 and SLCO1B and mycophenolic acid (MPA) pharmacokinetics, and MPA-related diarrhea and leukopenia in 338 kidney transplant recipients...
  14. doi request reprint AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism
    Madelon van Agteren
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Ther Drug Monit 30:439-44. 2008
    ..There also was no association between this variant genotype and the incidence of diarrhea or leucopenia, two adverse events for which a role for AcylMPAG has been suggested...
  15. doi request reprint Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration
    Albert Jan L H J Aarnoudse
    Department of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands
    Pharmacogenet Genomics 18:299-305. 2008
    ..The goal of this study was to establish ABCB1 genotype effect on digoxin blood concentrations in a large cohort of chronic digoxin users in a general Dutch European population...
  16. doi request reprint A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine
    Dennis A Hesselink
    Erasmus MC, Department of Internal Medicine, Division of Nephrology and Renal Transplantation, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Pharmacogenomics 9:783-9. 2008
    ....
  17. doi request reprint Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study
    Claire Siemes
    Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Steroids 75:1024-32. 2010
    ..To study if polymorphisms in genes encoding for CYP3A enzymes, that play a role in steroid hormone metabolism, affect steroid hormone serum levels and prostate cancer incidence or mortality...
  18. doi request reprint Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly
    Monique J Bijl
    Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pharmacogenomics 10:541-7. 2009
    ..Relative to extensive metabolizers, these poor metabolizers may have lower baseline serotonin concentrations in various brain regions, and may be more prone to depression or anxiety...
  19. doi request reprint Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study
    Laure Elens
    Departments of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands
    Pharmacogenet Genomics 21:861-6. 2011
    ....
  20. ncbi request reprint ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients
    Bronno van der Holt
    Department of Trials and Statistics HOVON Dutch Belgian Hemato Oncology Cooperative Group Data Center, Erasmus MC Daniel den Hoed Cancer Center and Sophia Children s Hospital, Rotterdam, The Netherlands
    Clin Pharmacol Ther 80:427-39. 2006
    ....
  21. doi request reprint Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males
    Matthijs L Becker
    Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Pharmacogenomics 10:1743-51. 2009
    ....
  22. doi request reprint Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
    Matthijs L Becker
    Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands
    Pharmacogenet Genomics 20:38-44. 2010
    ..In this study, we assessed whether there exists an interaction between these two polymorphisms...
  23. doi request reprint Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism
    Ferdi Sombogaard
    Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands
    Pharmacogenet Genomics 19:626-34. 2009
    ..The aim of this study was to correlate eight different single nucleotide polymorphisms of the IMPDH type II gene to the activity of the IMPDH enzyme to explain between-patient differences in IMPDH activity...
  24. doi request reprint Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy
    Matthijs L Becker
    Department of Epidemiology, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Pharmacoepidemiol Drug Saf 19:75-81. 2010
    ..These events may indicate that statin plasma levels were too high and resulted in an adverse drug reaction or a too strong reduction in cholesterol level...
  25. doi request reprint The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients
    Laure Elens
    Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    Pharmacogenet Genomics 22:373-80. 2012
    ..In the present study, the clinical impact of this single-nucleotide polymorphism was investigated in a cohort of patients receiving a CsA-based immunosuppressive regimen...
  26. doi request reprint A genome-wide association study of acenocoumarol maintenance dosage
    Martina Teichert
    Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
    Hum Mol Genet 18:3758-68. 2009
    ..Besides age, gender, body mass index and target INR, one polymorphism within each of the VKORC1, CYP2C9, CYP4F2 and CYP2C18 genes could explain 48.8% of acenocoumarol dosage variation...
  27. pmc OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users
    Matthijs L Becker
    Department of Epidemiology, Erasmus MC, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Neurogenetics 12:79-82. 2011
    ..34 defined daily dose higher (95% CI 0.064, 0.62; p=0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p=0.045)...
  28. doi request reprint CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen
    Rikje Ruiter
    Department of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pharmacogenomics 11:1367-75. 2010
    ..We investigated the hypothesis that CYP2C19*2 and *3 variants, known for their lack of enzyme activity, are associated with an increased breast cancer mortality rate in patients using tamoxifen...
  29. doi request reprint CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance
    Nilufar Pashaee
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus MC, Rotterdam, The Netherlands
    Ther Drug Monit 33:369-71. 2011
    ..The risk of long-term chronic allograft nephropathy and graft loss after kidney transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) clearance...
  30. pmc CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
    Anne Joy M de Graan
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 19:3316-24. 2013
    ..Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity...
  31. doi request reprint Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study
    Raymond Noordam
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Psychopharmacol 33:546-50. 2013
    ..In summary, this study showed that genetic variation in the ABCB1 gene might play a role in the risk of switching and discontinuation of antidepressant therapy but the clinical relevance is limited. ..
  32. doi request reprint Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus
    Ramin Vafadari
    Department of Internal Medicine, University Medical Center, Rotterdam, The Netherlands
    Ther Drug Monit 35:459-65. 2013
    ..Here the influence of this SNP on the biological effect of tacrolimus was studied...
  33. doi request reprint Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Pharmacogenet Genomics 23:148-55. 2013
    ..Whereas midazolam is metabolized by both CYP3A4 and CYP3A5, erythromycin is exclusively oxidized by CYP3A4...
  34. doi request reprint CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Pharmacogenomics 14:137-49. 2013
    ..The CYP3A4*22 allele was recently reported to be associated with reduced CYP3A4 activity. We investigated the impact of this allele on the metabolism of the CYP3A-phenotyping probes, midazolam (MDZ) and erythromycin...
  35. pmc Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants
    Monique J Bijl
    Department of Epidemiology and Biostatistics, Erasmus MC, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Br J Clin Pharmacol 65:558-64. 2008
    ..Reduced enzyme activity potentially leads to increased toxicity of antidepressants, but the relevance of genotyping for clinical practice is unclear. Most clinical studies suffer from small numbers of patients...
  36. doi request reprint Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation
    Rachida Bouamar
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus MC, Rotterdam, The Netherlands
    Ther Drug Monit 33:178-84. 2011
    ..The authors studied the influence of these SNPs on CsA pharmacokinetics as well as on the incidence of biopsy-proven acute rejection (BPAR) and renal function after kidney transplantation...
  37. doi request reprint A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Chem 57:1574-83. 2011
    ..Tac pharmacokinetics varies between individuals and thus complicates its use in preventing rejection after kidney transplantation. This variability might be caused by genetic polymorphisms in metabolizing enzymes...
  38. doi request reprint CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus MC, Rotterdam, The Netherlands
    Pharmacogenet Genomics 18:339-48. 2008
    ..We studied the influence of the CYP3A5(*)3 allele, which results in the absence of CYP3A5 protein, on tacrolimus dose and exposure, as well as the incidence of biopsy-proven acute rejection (BPAR) after renal transplantation...
  39. doi request reprint Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines
    Laure Elens
    Louvain Centre for Toxicology and applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Universite Catholique de Louvain, Brussels, Belgium Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands and Laboratory of Analytical Biochemistry, Surgery and Abdominal Transplantation Division, and Laboratory of Immuno haematology, Cliniques Universitaires St Luc, Universite Catholique de Louvain, Brussels, Belgium
    Ther Drug Monit 35:608-16. 2013
    ..However, the pharmacokinetic (PK) parameters assessed in previous studies were limited on single time point whole blood trough concentrations (C0) during routine follow-up of the patient after transplantation...
  40. doi request reprint Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands Louvain Centre for Toxicology and Applied Pharmacology LTAP Department, Universite Catholique de Louvain, Brussels, Belgium Department of Internal Medicine and Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands Department of Nephrology, Charite University, Berlin, Germany Department of Nephrology, Leiden University Medical Centre, Leiden, the Netherlands Surgery and Abdominal Transplantation Unit Cliniques universitaires St Luc, Universite Catholique de Louvain, Brussels, Belgium and Department of Nephrology, University of Leuven, Leuven, Belgium
    Ther Drug Monit 36:71-9. 2014
    ..The aim of this study was to investigate the impact of the POR*28 allele on Tac and cyclosporine A (CsA) immunosuppressive therapies...
  41. doi request reprint CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
    Laure Elens
    Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Rotterdam, The Netherlands
    Pharmacogenomics 14:47-62. 2013
    ..This review will summarize the current literature on phenotypes linked to this new promising CYP3A4 genetic marker SNP and discusses the potential clinical relevance...
  42. pmc Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel
    Anne Joy M de Graan
    Department of Medical Oncology and Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 18:4433-40. 2012
    ..We hypothesized that (i) liver uptake of docetaxel is mediated by the polymorphic solute carriers OATP1B1 and OATP1B3 and (ii) inherited genetic defects in this process may impair systemic drug elimination...
  43. ncbi request reprint Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
    Dennis A Hesselink
    Department of Internal Medicine, Renal Tranplant Unit, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 74:245-54. 2003
    ..The low oral bioavailability of calcineurin inhibitors is thought to result from the actions of the metabolizing enzymes cytochrome P450 (CYP) 3A4 and CYP3A5 and the multidrug efflux pump P-glycoprotein, encoded by MDR-1...
  44. pmc Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study
    Matthijs L Becker
    Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
    Diabetes 58:745-9. 2009
    ..We studied the effect of single nucleotide polymorphisms (SNPs) in the SLC47A1 gene on the A1C-lowering effect of metformin...
  45. ncbi request reprint Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:2719-26. 2007
    ..The purpose of this study was to determine the effects of cigarette smoking on the pharmacokinetics and adverse effects of irinotecan...
  46. ncbi request reprint Influence of ketoconazole on the fecal and urinary disposition of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 60:569-79. 2007
    ....
  47. doi request reprint Genetic polymorphisms in IL-2, IL-10, TGF-β1, and IL-2RB and acute rejection in renal transplant patients
    Zhigang Chen
    Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands Department of Hospital Pharmacy, Beijing Jishuitan Hospital, Beijing, China
    Clin Transplant 28:649-55. 2014
    ..SNPs in the investigated cytokines and their receptors were not associated with the risk of AR. Genotyping patients for these SNPs is unlikely to aid the clinician in adjusting the immunosuppressive therapy for individual patients...
  48. ncbi request reprint MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine
    Albert L H J Aarnoudse
    Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 80:367-74. 2006
    ..We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein...
  49. doi request reprint Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
    Anne Joy M de Graan
    Erasmus Medical Center Daniel den Hood Cancer Center, University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 29:3240-6. 2011
    ..In this pharmacokinetic study, we investigated the value of dextromethorphan, a known probe drug for both CYP2D6 and CYP3A enzymatic activity, as a potential phenotyping probe for tamoxifen pharmacokinetics...
  50. doi request reprint Predicting paclitaxel-induced neutropenia using the DMET platform
    Annemieke J M Nieuweboer
    Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Pharmacogenomics 16:1231-41. 2015
    ..The use of paclitaxel in cancer treatment is limited by paclitaxel-induced neutropenia. We investigated the ability of genetic variation in drug-metabolizing enzymes and transporters to predict hematological toxicity...
  51. pmc 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
    Anne Joy M de Graan
    Department of Medical Oncology, Erasmus MC Cancer Institute, s Gravendijkwal 230, 3015CE, Rotterdam
    Br J Clin Pharmacol 80:560-8. 2015
    ..In this study, we evaluated the endogenous CYP3A4 marker 4β-hydroxycholesterol (4β-OHC) as a potential individual taxane PK predictor...
  52. doi request reprint Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications
    Laure Elens
    Department of Clinical Chemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Mol Diagn Ther 16:331-45. 2012
    ..However, at present, some interesting findings can be highlighted and offer potential value to assist clinicians in decision making...
  53. pmc The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
    Saskia N de Wildt
    Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children s Hospital, Sk3140, Dr Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands
    Eur J Clin Pharmacol 67:1231-41. 2011
    ..The aim of this study was to evaluate the effect of these covariates on tacrolimus dose requirements in the immediate post-transplant period in pediatric kidney and liver recipients...
  54. ncbi request reprint Sequencing: not always the "gold standard"
    Ilse P van der Heiden
    Department of Clinical Chemistry, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Clin Chem 50:248-9. 2004
  55. ncbi request reprint Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment
    Ron H J Mathijssen
    Department of Medical Oncology and Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 42:141-8. 2006
    ....
  56. doi request reprint A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform
    Anne Joy M de Graan
    Authors Affiliations Departments of Medical Oncology, Clinical Chemistry, and Trials and Statistics, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee and Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 19:5210-7. 2013
    ....
  57. doi request reprint Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals
    Sandra G Heil
    Department of Clinical Chemistry AKC, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Ther Drug Monit 34:153-9. 2012
    ..In this study, the authors investigated whether common ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles are associated with plasma concentrations of EFV and NVP in HIV-infected individuals...
  58. ncbi request reprint A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels
    Pauline Smit
    Department of Internal Medicine, Room Ee585, Erasmus Medical Center, Dr Molewaterplein 40, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 90:5313-6. 2005
    ..Due to a replacement of part of the CYP3A7 promoter with a sequence identical with the same region in the CYP3A4 promoter (referred to as CYP3A7*1C), some individuals still express a variant of the CYP3A7 gene later in life...
  59. doi request reprint General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect
    Sylvia A Obermann-Borst
    Division of Obstetrics and Prenatal Medicine, Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
    Am J Obstet Gynecol 204:236.e1-8. 2011
    ..We sought to investigate maternal and child functional MDR1 C3435T polymorphism, periconception medication, folic acid use, and the risk of a congenital heart defect (CHD) in the offspring...
  60. ncbi request reprint Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 96:1585-92. 2004
    ..We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin metabolism and midazolam clearance, and the metabolism of irinotecan and its active metabolite SN-38...
  61. doi request reprint CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people
    Maren I Blonk
    Department of Hospital Pharmacy, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pharm World Sci 32:26-9. 2010
    ..The objective of this study is to investigate the association between CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls...
  62. doi request reprint Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate
    Bart J B Bliek
    Division of Obstetrics and Prenatal Medicine, Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Am J Med Genet A 149:2088-92. 2009
    ..2, 95% CI = 1.0-369.2). These data suggest that mothers who carry the ABCB1 3435C > T polymorphism are at significantly increased risk for having offspring with CL/P, especially mothers using medication in the periconceptional period...
  63. doi request reprint Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer
    Monique J Roobol
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Urol 64:530-9. 2013
    ..Evidence from randomized trials on the effects of screening for prostate cancer (PCa) on disease-specific mortality accumulates slowly with increasing follow-up...
  64. pmc A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
    Su Jun Lee
    Department of Clinical Chemistry, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Drug Metab Dispos 35:67-71. 2007
    ..No additional examples of this allele were identified. In summary, individuals carrying the rare CYP3A5*11 allele are predicted to have lower metabolism of CYP3A5 substrates than individuals expressing CYP3A5*3...
  65. pmc Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks
    Laure Elens
    Louvain Drug Research Institute LDRI, Universite Catholique de Louvain UCL, Brussels, Belgium Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam
    Br J Clin Pharmacol 77:715-28. 2014
    ..The purpose of the present review is to picture the current status of CNI pharmacogenetics and to discuss the most promising leads that have been followed so far. ..
  66. doi request reprint Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation
    Ozlem Tapirdamaz
    Departments of aGastroenterology and Hepatology bInternal Medicine cClinical Chemistry dSurgery eHospital Pharmacy, Clinical Pharmacology Unit Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Pharmacogenet Genomics 24:427-35. 2014
    ..We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT...
  67. doi request reprint P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study
    Violette M G J Gijsen
    Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children s Hospital, Rotterdam, the Netherlands Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON, Canada Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands Departments of Oncology Medicine Pharmacology Physiology Biophysics, Georgetown University Medical Center, Washington, DC and Department of Medicine, University of Western Ontario, London, ON, Canada
    Ther Drug Monit 36:152-8. 2014
    ..The authors aimed to evaluate the additional contribution of POR*28 to early tacrolimus disposition in pediatric kidney transplant recipients...
  68. doi request reprint The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
    Dennis A Hesselink
    Division of Nephrology and Renal Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Room D 427, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Clin Pharmacokinet 53:123-39. 2014
    ..The role of pharmacogenetics in tacrolimus pharmacodynamics should be explored further by the study of intra-lymphocyte and tissue tacrolimus concentrations. ..
  69. ncbi request reprint Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    Cancer Biol Ther 5:833-9. 2006
    ..We investigated if high-dose ketoconazole, a potent CYP3A inhibitor, could result in a uniform reduction of docetaxel clearance and reduce the inter-individual variability in docetaxel AUC and clearance...
  70. ncbi request reprint The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
    Loes E Visser
    Pharmacoepidemiology Unit, Department of Internal Medicine, Easmus MC, Rotterdam, The Netherlands
    Pharmacogenetics 14:27-33. 2004
    ..Phenprocoumon appears to be a clinically useful alternative in patients carrying the CYP2C9*2 and *3 alleles...
  71. doi request reprint MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patients
    Adrian Kruit
    Department of Clinical Chemistry, St Antonius Hospital, Nieuwegein, The Netherlands
    Clin Biochem 42:662-5. 2009
    ..CA 15-3 is a widely used tumor marker for breast cancer. We have investigated whether the MUC1 568 A/G polymorphism can influence CA 15-3 levels in healthy women and patients with breast tumors...
  72. doi request reprint Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
    Walter J Loos
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    J Pharm Biomed Anal 54:387-94. 2011
    ..7 to 110.6%. The applicability of the bioanalytical method was demonstrated and is currently implemented in a clinical trial to study DM as probe-drug for individualized tamoxifen treatment in breast cancer patients...
  73. ncbi request reprint Genetic techniques for pharmacogenetic analyses
    Tahar van der Straaten
    Dept Clinical Chemistry, Erasmus MC Rotterdam, The Netherlands
    Curr Pharm Des 16:231-7. 2010
    ..In this review we identify and evaluate the information present in the literature on genotyping assays that are currently used for pharmacogenetic analyses, and discuss the advantages and disadvantages of these techniques...
  74. ncbi request reprint Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors
    Otto Soepenberg
    Daniel den Hoed Cancer Center, Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 11:1504-11. 2005
    ..To characterize the maximum-tolerated dose, recommended dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and food effect of orally administered irinotecan formulated as new semisolid matrix capsules...
  75. ncbi request reprint Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
    Dennis A Hesselink
    Department of Internal Medicine, Renal Transplant Unit, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    Clin Pharmacol Ther 76:545-56. 2004
    ....
  76. ncbi request reprint Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study
    Floris A de Jong
    Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Department of Medical Oncology, Room AS 15, Groene Hilledijk 301, NL 3075 EA Rotterdam, The Netherlands
    Oncologist 11:944-54. 2006
    ..Based on a pilot study, we hypothesized that concomitant administration of the antibiotic neomycin would diminish exposure of the gut to SN-38 and ameliorate the incidence and severity of diarrhea...
  77. doi request reprint Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
    Flip H Jansen
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 57:921-7. 2010
    ..Novel markers for prostate cancer (PCa) detection are needed. Total prostate-specific antigen (tPSA) and percent free prostate-specific antigen (%fPSA=tPSA/fPSA) lack diagnostic specificity...
  78. ncbi request reprint Effects of the renin-angiotensin system genes and salt sensitivity genes on blood pressure and atherosclerosis in the total population and patients with type 2 diabetes
    Mojgan Yazdanpanah
    Genetic Epidemiology Unit, Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Diabetes 56:1905-12. 2007
    ..04 mm, P = 0.02). We found that among type 2 diabetic patients, mean systolic blood pressure, pulse pressure, and risk of hypertension increased with the number of risk genotypes for the RAS genes and the salt sensitivity genes...
  79. doi request reprint ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis
    Maurits C F J de Rotte
    Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Rheumatol 39:2032-40. 2012
    ..To individualize treatment strategies, the genetic determinants of response to MTX should be identified...
  80. ncbi request reprint CYP3A5 variant allele frequencies in Dutch Caucasians
    Ron H N van Schaik
    Department of Clinical Chemistry, Sophia Children s Hospital, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Clin Chem 48:1668-71. 2002
    ..Detection of CYP3A5 variant alleles, and knowledge about their allelic frequency in specific ethnic groups, is important to establish the clinical relevance of screening for these polymorphisms to optimize pharmacotherapy...
  81. ncbi request reprint Cardiac aldosterone in subjects with hypertrophic cardiomyopathy
    Wenxia Chai
    Department of Pharmacology, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    J Renin Angiotensin Aldosterone Syst 7:225-30. 2006
    ..This finding raises the need for studies determining the benefit of aldosterone blockade in HCM...
  82. ncbi request reprint Factors affecting cytochrome P-450 3A activity in cancer patients
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:8341-50. 2004
    ..The purpose is to identify the demographic, physiologic, and inheritable factors that influence CYP3A activity in cancer patients...
  83. doi request reprint Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants
    Karel Allegaert
    Neonatal Intensive Care Unit, University Hospitals, Campus Gasthuisberg, B 3000 Leuven, Belgium
    Pediatr Res 63:674-9. 2008
    ..Besides compound-specific relevance, CYP2D6 iso-enzyme specific data on in vivo ontogeny of O-demethylation can contribute to safer and more effective administration of drugs metabolized by the same route in this population...
  84. ncbi request reprint Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
    Erin R Lepper
    Science Applications International Corporation Frederick, Maryland, USA
    Clin Cancer Res 11:7398-404. 2005
    ..To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe...
  85. ncbi request reprint Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
    Mark David Levin
    Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
    J Antimicrob Chemother 60:1104-7. 2007
    ..We examined the relationship between cytochrome P450 polymorphisms and hepatotoxicity in immunocompromised patients predominantly receiving oral formulations of voriconazole...
  86. ncbi request reprint UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease
    Deepika S Darbari
    Center for Cancer and Blood Disorders, Children s National Medical Center, Washington, DC 20010, USA
    Am J Hematol 83:200-2. 2008
    ..1 +/- 2.7 vs. 15.7 +/- 9.4 for M3G/M) (P = 0.03). Presence of UGT2B7 -840G allele is associated with significantly reduced glucuronidation of morphine and thus contributes to the variability in hepatic clearance of morphine in SCD...
  87. ncbi request reprint Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery
    Mariska Y M Peeters
    Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands
    Anesthesiology 104:466-74. 2006
    ..To support safe and effective use of propofol in nonventilated children after major surgery, a model for propofol pharmacokinetics and pharmacodynamics is described...
  88. ncbi request reprint Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations
    Elke H J Krekels
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Greenford, UK
    Expert Opin Pharmacother 8:1787-99. 2007
    ....
  89. ncbi request reprint Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery
    Mariska Y M Peeters
    Department of Clinical Pharmacy, St Antonius Hospital, The Netherlands
    Anesthesiology 105:1135-46. 2006
    ..Because information on the optimal dose of midazolam for sedation of nonventilated infants after major surgery is scant, a population pharmacokinetic and pharmacodynamic model is developed for this specific group...